News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Third Party Research Study Demonstrates Pluristem Therapeutics (PSTI)'s PLX-PAD Cells' Safety in Human Lung Models of Pulmonary Hypertension


4/29/2013 11:46:40 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HAIFA, Israel, April 29, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that independent researchers from the Queensland Lung Transplant Service at the University of Queensland, Australia demonstrated that following infusion of Pluristem's PLX (Placental eXpanded) cells in a human lung model of pulmonary arterial hypertension (PAH), blood flows were maintained and no adverse hemodynamic effects were noted.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES